MENLO PARK, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Jim Schoeneck, will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference in New York City on Tuesday, Nov. 15, 2011. The presentation is scheduled for 3:30 pm eastern time.
The presentation will be webcast live and the webcast can be accessed via the investor relations page of the Depomed website at www.depomed.com. It can also be accessed directly via the following link: http://wsw.com/webcast/lz11/depo/.
A recording of the webcast will be archived for up to 30 days on the company's website.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise ™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529